bearish
Ascletis Pharma (歌礼制药) Post-Listing: Thoughts on Liquidity and Bull Cases
402 Views06 Aug 2018 16:34
Ascletis Pharma, the first biotech companies to list in Hong Kong without a profit under the amended listing rules, debuted last week with poor...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Coverage Weekly Update (18 August 2018)18 Aug 2018
- Ascletis Pharma: Invalidation of Gilead Patents Won't Help15 Aug 2018
- ECM Coverage Weekly Update (11 August 2018)11 Aug 2018
- Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)23 Jul 2018
- Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)23 Jul 2018
x